Silence Therapeutics jumps 59% on Merck takeover

Silence Therapeutics (SLN) surged 59% to $6.11 after agreeing to a $1.3B takeover by Merck KGaA. Merck will pay $20 per ADS, a 130% premium. The deal values Silence's equity at $1.3B and is expected to close in Q1 2027, pending approvals. Silence's drug development programs, including divesiran for polycythaemia vera, will benefit from Merck's resources.

Original reporting
Published Oct 19, 2026, 3:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 3:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Silence Therapeutics jumps 59% on Merck takeover — source image
Decision brief

The 30-second read

$SLNBullishHigh
01

Why it matters

The deal adds a siRNA platform to Merck's portfolio and provides an exit for Silence shareholders.

02

Market read

First disclosure of a $1.3 billion acquisition with a 130% premium, causing a 59% stock jump.

03

What to watch

Potential integration risks and the need for shareholder approval could delay value realization.

Relevance 9/10Novelty 9/10Timing: immediate today

Background

Merck KGaA is expanding its rare‑disease pipeline through acquisitions.

Company-level read

Ticker impact

$SLNBullishHigh confidence
Context

Silence Therapeutics shares surged 59% after announcing a $1.3 billion takeover by Merck KGaA.

Expected impact

upward pressure as the market prices in the cash premium

Evidence & confidence

Deal is first disclosed, includes a 130% cash premium and triggers a large intraday move.

Market effects

Strengthens the rare‑disease biotech segment and may boost peer valuations.

European pharma M&A activity could see heightened attention.

Large‑cap pharma interest may spill over to global biotech sentiment.

Counterpoint

If regulatory clearance stalls, the premium could evaporate and the stock may retrace.

Key entities

  • Silence Therapeutics

    Clinical‑stage biotech developing siRNA therapies.

  • Merck KGaA

    German pharmaceutical and technology group acquiring Silence.

Related articles

$MRKHigh

Why Merck (MRK) Stock Is Down Today

Merck (MRK) shares fell 3.8% after the company discontinued the BELLWAVE clinical program for nemtabrutinib, citing potential risks outweighing benefits in a Phase 3 trial. The decision impacts multiple studies, marking a pipeline setback for the drugmaker. Merck's latest earnings report had shown revenue growth and pipeline activity before this development.

$MRKHigh

Merck wins all 14 U.S. patent reviews against Halozyme

Merck (MSD) won all 14 U.S. patent reviews against Halozyme, securing its Keytruda Qlex cancer immunotherapy's subcutaneous injection technology. The Patent Trial and Appeal Board ruled all challenged claims unpatentable. Keytruda Qlex sales reached $830M in Q3, 9.7% of total Keytruda sales. Halozyme may appeal, and a patent infringement lawsuit is ongoing.